Pharmacogenomic Testing for Warfarin Response | CMS Coverage Update

Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for pharmacogenomic testing for warfarin response, effective May 15, 2026. Here's what billing teams need to do before that date.

CMS pharmacogenomic testing for warfarin response coverage policy has been a moving target for years, and this modification adds another layer your billing team needs to track. The Centers for Medicare & Medicaid Services does not list a specific policy code for this change — it's referenced without a formal NCD or LCD number in the current update. The policy does not list specific CPT or HCPCS codes in the available documentation, which creates real ambiguity for charge capture and claim submission. Warfarin pharmacogenomic testing billing has historically lived in a gray zone between covered genomic medicine and experimental designation, and this update shifts that line.

Quick-Reference Table

CMS Pharmacogenomic Testing for Warfarin Response Coverage Criteria and Medical Necessity Requirements 2026

This is where most billing teams will get tripped up. CMS pharmacogenomic testing for warfarin response coverage policy hinges on medical necessity — and the definition of medical necessity here is stricter than many practices assume.

Warfarin is a narrow therapeutic index drug. Small genetic variations in CYP2C9 and VKORC1 genes can dramatically change how a patient metabolizes it. The clinical rationale for testing is solid. But CMS has historically drawn a sharp line between testing that guides initial dosing decisions and testing used for monitoring or after stable dosing is established.

The real issue is the "when" question. CMS coverage for pharmacogenomic testing in this context has generally applied to patients initiating warfarin therapy — not patients who are already stable on a dose. If your practice is ordering this testing mid-therapy or at follow-up visits, those claims are at high risk for denial. Medical necessity documentation needs to tie directly to the initiation decision, not general clinical curiosity.

Prior authorization requirements for pharmacogenomic testing vary by Medicare Administrative Contractor. Some MACs have issued local coverage determinations that impose prior auth requirements on top of the national framework. Check with your MAC before May 15, 2026 — don't assume the national policy eliminates local requirements.

CMS Pharmacogenomic Testing for Warfarin Response Exclusions and Non-Covered Indications

CMS has not historically covered pharmacogenomic testing for warfarin response when it is ordered outside of initiation of therapy. That's the clearest exclusion to know.

Testing ordered for patients already stabilized on a warfarin dose is not covered. CMS treats this as testing that does not change clinical management — and "no change to management" is a fast path to a claim denial. Your medical necessity documentation needs to show that the test result will directly affect the dosing decision, before the decision is made.

Repeat testing is also excluded. This is not a panel you can order annually or at each visit. One-time testing tied to a specific clinical decision point is the coverage model. If your billing team sees repeat orders in a patient's history, flag those before submission.

The broader category of pharmacogenomic testing outside of warfarin — even if ordered at the same encounter — is not covered under this policy. Don't bundle unrelated genomic tests onto the same claim and expect carryover coverage.

Coverage Indications at a Glance

The available policy documentation does not list specific indications with formal coverage designations. The table below reflects the coverage framework based on CMS's established position on pharmacogenomic testing for warfarin response.

CMS Warfarin Pharmacogenomic Testing Billing Guidelines and Action Items 2026

This modification has direct consequences for your revenue cycle. Here's what to do now.

CPT, HCPCS, and ICD-10 Codes for Pharmacogenomic Testing for Warfarin Response Under This CMS Policy

The available policy documentation does not list specific CPT, HCPCS, or ICD-10 codes. This is a real gap in the published policy data, and it creates a practical problem for your billing team.

Do not assume which codes apply. Pharmacogenomic testing codes exist across several code families, and CMS and your MAC recognize specific codes for specific tests. Using the wrong code — even for a covered test — generates a claim denial.

How to Find the Right Codes

Contact your Medicare Administrative Contractor directly. Ask for the covered codes under their local coverage determination for pharmacogenomic testing for warfarin response. If your MAC has not issued an LCD on this topic, ask how they process claims for this testing and which CPT codes they recognize.

Check the CMS LCD database at cms.gov. Search for "pharmacogenomic" or "warfarin" in the LCD search tool. Your MAC's specific LCD will list covered codes if coverage has been formalized at the local level.

Work with your clinical laboratory. If you're ordering send-out testing, the reference lab's billing team can tell you which codes they use and how they've handled Medicare reimbursement for these tests. That information is useful — but confirm it with your MAC before you rely on it.

A Note on Code Gaps in This Policy

The absence of specific codes in the policy documentation is unusual and worth flagging to your compliance officer. When CMS modifies a coverage policy without listing specific codes, it often means the code-level coverage is governed at the MAC level — which means your reimbursement rates, prior authorization requirements, and coverage criteria may differ from a practice in a different MAC jurisdiction. This is not a uniform national policy in practical terms.